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Abstract Niemann-Pick disease, type C1 (NPC1) is an
autosomal recessive lipid storage disorder in which a path-
ological cascade, including neuroinflammation occurs.
While data demonstrating neuroinflammation is prevalent
in mouse models, data from NPC1 patients is lacking. The
current study focuses on identifying potential markers of
neuroinflammation in NPC1 from both the Npc1 mouse
model and NPC1 patients. We identified in the mouse model
significant changes in expression of genes associated with
inflammation and compared these results to the pattern of
expression in human cortex and cerebellar tissue. From gene
expression array analysis, complement 3 (C3) was increased
in mouse and human post-mortem NPC1 brain tissues. We
also characterized protein levels of inflammatory markers in
cerebrospinal fluid (CSF) from NPC1 patients and controls.
We found increased levels of interleukin 3, chemokine
(C-X-C motif) ligand 5, interleukin 16 and chemokine li-
gand 3 (CCL3), and decreased levels of interleukin 4, 10, 13
and 12p40 in CSF from NPC1 patients. CSF markers were
evaluated with respect to phenotypic severity. Miglustat
treatment in NPC1 patients slightly decreased IL-3, IL-10
and IL-13 CSF levels; however, further studies are needed to
establish a strong effect of miglustat on inflammation
markers. The identification of inflammatory markers with
altered levels in the cerebrospinal fluid of NPC1 patients
may provide a means to follow secondary events in NPC1
disease during therapeutic trials.
Introduction
Niemann-Pick disease, type C1 (NPC1) is a fatal, genetic
disorder that results in severe, progressive neurodegeneration.
Mutations of the NPC1 gene result in a loss of function
of the NPC1 protein (Carstea et al 1997), thereby, impairing
cholesterol and glycosphingolipid trafficking. A deficiency
of NPC1 protein function results in an accumulation of
unesterified cholesterol and glycosphingolipids in the late
endosomes/lysosomes (Pentchev et al 1987; Zervas et al
2001; Vanier and Millat 2003). Following the initial defect,
a complex cascade of pathological events occurs in NPC1
including oxidative stress (Reddy et al 2006; Zampieri et al
2009; Fu et al 2010; Porter et al 2010; Klein et al 2011;
Vazquez et al 2011), neurofibrillary tangle formation (Love
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et al 1995; Suzuki et al 1995), and neuronal apoptosis
among others (Ong et al 2001; Sarna et al 2003; Wu et
al 2005). Clinical symptoms in NPC1 patients are het-
erogeneous and include hepatosplenomegaly, ataxia, vertical
gaze palsy, and dementia, in which progression in neurolog-
ical severity occurs over time (Vanier 2010; Yanjanin et al
2010). To date, there is no FDA-approved therapy for NPC1.
However, reports have indicated that treatment with miglustat,
(Zavesca®), an imino sugar that blocks glycosphingolipid
synthesis, slows the neurological progression of the disease
in both animal models and NPC1 patients (Patterson et al
2007; Pineda et al 2009; Patterson et al 2010; Wraith et al
2010).Miglustat has been approved for the treatment of NPC1
by the European Medicines Agency. Currently, miglustat is
only FDA-labeled for the treatment of Gaucher disease but has
been used off-label for NPC1. Recently, 2-hydroxypropyl-β-
cyclodextrin (HP-β-CD) has shown promise as a potential
therapy for NPC1. HP-β-CD has been demonstrated to main-
tain neurological function and reduce the storage burden in
both mouse and feline models of NPC1 disease (Davidson et
al 2009; Liu et al 2009; Ramirez et al 2010; Ward et al 2010;
Aqul et al 2011).
Neuroinflammation is a common feature found in many
disorders particularly those affecting the central nervous
system (CNS). Within the CNS, the innate immune system
of microglia, astrocytes and perivascular macrophages serve
as a first line of defense (Graeber et al 2011; Veerhuis et al
2011). The activation of microglia and astrocytes during the
inflammation process results in a morphological change and
is characterized by positive staining for CD68 and GFAP,
respectively (Eng et al 2000; Kunisch et al 2004; Marin-
Teva et al 2012). Secreted proteins from both microglia and
astrocytes can be used as inflammation markers in cerebro-
spinal fluid-based analyses [as reviewed (Suk 2010)].
The first evidence of neuroinflammation in the Npc1
mouse is the activation of microglia at approximately
2 weeks post birth. This activation begins the neurodegen-
erative cascade with subsequent marked activation of astro-
cytes around 4 weeks post birth, beneath the Purkinje cell
layer corresponding to the sites of early apoptosis in NPC1
disease (Baudry et al 2003). Smith et al tested the effective-
ness of non-steroidal anti-inflammatory drugs in Npc1 mu-
tant mice where a positive response with respect to survival
was observed, as well as reduced microglial activation
(Smith et al 2009). Pressey and co-workers investigated
the effect of Npc1 deficiency on brain pathology at different
stages of the disease process (Pressey et al 2012). The
thalamus and cerebellum have been identified as particularly
vulnerable to neurodegeneration, showing early activation
of glia from 3 weeks post birth (Pressey et al 2012). The
relationship between glia and neurons is variable within
different brain regions, suggesting that the mechanism un-
derlying the neuroinflammation in various brain regions
may differ. Recently miglustat treatment in the feline model
of NPC1 was shown to improve Purkinje cell survival, and
reduced lipid storage and microglial activation suggesting
that neuroinflammation may be affected with miglustat
(Stein et al 2012).
Microglial activation in chronic neurodegeneration can
be beneficial, harmful or non-significant (Ransohoff and
Brown 2012). The role of inflammation in the disease pro-
gression of NPC1 has yet to be determined. It is particularly
unclear whether neuroinflammation is a primary pathologi-
cal process, or a secondary event resulting from the initial
genetic and trafficking defects. Recent data suggest that
neuroinflammation in NPC1 is a secondary process (Lopez
et al 2012a, b). While some studies have discussed the
prevalence of inflammation in Npc1 mouse brain tissue
and the potential benefit of anti-inflammatory treatment,
human studies are lacking. Understanding the role of
neuroinflammation and identification of biomarkers associ-
ated with this aspect of NPC1 pathology will be of utility in
designing and translating potential therapies to NPC1
patients.
In an effort to further characterize and potentially
target therapeutic interventions along the neuropathogenic
cascade in NPC1, we sought to further understand the
neuroinflammation processes occurring in both Npc1 mice
and NPC1 patient brain tissue using differential expression
analysis. Our work additionally aimed at establishing which
inflammatory markers are altered in the cerebrospinal fluid
from NPC1 patients relative to controls. Using discovery
and targeted based approaches, several inflammation
markers were found to be altered in the Npc1 mouse model
as well as in cerebrospinal fluid from NPC1 patients. These
data will provide a more comprehensive understanding of
the array of biological processes that are involved in NPC1
pathology and provide a deeper understanding of the disease
process while concurrently providing potential biomarkers
for monitoring disease progression and evaluating potential
therapeutic agents efficacy.
Materials and methods
Animal breeding and tissue isolation Animal work was
performed under an NICHD Animal Care and Use
Committee-approved animal study protocol. Heterozygous
Npc1+/− mice (BALB/c Nctr-Npc1m1N/J strain) were
intercrossed to obtain control (Npc1+/+) and mutant
(Npc1−/−) littermates. For tissue collection, female Npc1−/−
and Npc1+/+ mice were sacrificed at 1, 3, 5, 7, 9 and
11 weeks of age using a rising concentration of carbon
dioxide. The cerebral cortex was collected, flash frozen
and stored at −80 °C until use. Mice homozygous for the
Ccl3-targeted mutation (B6.129P2-Ccl3tm1Unc/J strain,
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C57BL/6 genetic background) were used to test the effect of
Ccl3 deficiency on the NPC1 pathological process. Pups
were weaned 3 weeks after birth and subsequently had free
access to water and standard mouse chow. PCR genotyping
was performed using tail DNA. Primers and PCR conditions
to genotype the Npc1 locus were previously described
(Loftus et al 1997). Ccl3 locus genotype was determined
using two pairs of primers: the wild-type allele was ampli-
fied using the sense 5ATGAAGGTCTCCACCACTGC3
and the antisense 5AGTCAACGATGAATTGGCG3 (yield-
ing a 668 bp fragment); the mutant allele was amplified
using the sense 5CTTGGGTGGAGAGGCTATTC3 and
the antisense 5AGGTGAGATGACAGGAGATC 3 (yield-
ing a 280 bp fragment). The PCR conditions were as fol-
lows: 94 °C x 3 min., then 35 cycles of: 94 °C×30 s.,
66 °C×1 min., and 72 °C×1 min. The final step was to heat
at 72 °C×7 min and hold at 4 °C until further analysis.
Ccl3−/− mice were intercrossed with Npc1+/− mice to gener-
ate double-heterozygous animals, which were then
backcrossed to Npc1+/− for five generations. Double hetero-
zygous animals from the N5 generation were then
intercrossed to generate Npc1+/+Ccl3+/+, Npc1−/−Ccl3+/+,
Npc1−/−Ccl3+/− and Npc1−/−Ccl3−/− animals. Weight mea-
surements were determined twice a week from 4 weeks of
age. Animals were euthanized according to the ACUC pro-
tocol when they had lost 20 % of their maximal weight, and
this was defined as the age of death for survival analysis.
Human studies Human post-mortem tissue from age-matched
control and NPC1 patients was obtained from the NICHD
Blood and Tissue Bank (http://medschool.umaryland.edu/
btbank/). Cerebellar tissue was obtained from controls
UMB#754 (asthma attack), UMB#914 (motor vehicle acci-
dent), UMB#1841 (motor vehicle accident), UMB#5282
(asphyxia) and from NPC1 patients (confirmed mutations an-
notated from NM_000271.4) UMB#4237 (c.1628C>T/not
detected), UMB#4770 (c.3107C>T/c.3573_3574insACTT),
UMB#5372 (c.2842G>A/c.3182 T>C), UMB#M4002M
(c.973_974dup/not detected). Frontal cortex tissuewas received
from NPC1 patients UMB#4237, UMB#4770, UMB#5372,
UMB#M4002M, UMB#4214 (apparent c.3182 T>C homozy-
gosity), UMB#M4003M (c.3134_3135insG/c.3566A>G),
UMB#M4004M (c.2819C>T/c.3182 T>C) and controls
UMB#754 , UMB#914, UMB#1841, UMB#5282,
UMB#1573 (motor vehicle accident), UMB#4670 (accident),
UMB#5387 (drowned). No other data are available on these
individuals.
NPC1 patients included in this study were enrolled between
August 2006 and January 2011 in an Institutional Review
Board-approved, longitudinal, Natural History/Observational
trial at the National Institutes of Health (06-CH-0186,
NCT00344331). Written, informed consent was obtained for
all subjects. Assent was obtained when appropriate. Clinical
diagnosis was confirmed by filipin staining of fibroblasts and
NPC1 mutation analysis. Cerebrospinal fluid was collected via
lumbar puncture. Control cerebrospinal fluid was obtained from
30 gender and age-matched patients who were undergoing
cerebrospinal collection for another clinical indication. Four
control patients were febrile (>38.5 °C) at the time of cerebro-
spinal fluid collection, but none had elevated white blood cell
count or positive cultures. Age of control subjects ranged from
2weeks to 20 years at the time of cerebrospinal fluid collection.
Cerebrospinal fluid biomarker measurements were made
by Rules Based Medicine (Austin, TX) utilizing Multi-
Analyte Profiling Technology. Statistical calculations were
performed using GraphPad Prism. Log10 transformed con-
centration values were used to perform statistical analyses
on normally distributed datasets. The DAgostino and
Pearson omnibus normality test was used. For cases in
which less than 40 % of the total number of measurements
was missing due to being below the limit of detection
(LOD), the LOD/2 substitution method was used (Ganser
and Hewett 2010). C3 concentrations in CSF of a subset of
NPC1 patients covering the full age and severity range and
controls (N=14 and 11 respectively) were measured using
the GenWay Biotech kit, according to the manufacturers
recommendations. A 1:20 dilution of the CSF samples was
used to bring the sample concentration into the assay con-
centration range.
RNA isolation Frozen tissue samples, from a single mouse
cortex, or approximately 100 mg from post-mortem human
tissue, were homogenized in TRIzol (Life Technologies,
Carlsbad, California) using Omni-TipsTM (Omni International,
Marietta, GA). After chloroform addition and phase separation,
total RNA was purified using the RNeasy Mini Kit (Qiagen,
Valencia, CA) with an on-column DNase digestion step using
the RNase-Free DNase Set (Qiagen, Valencia, CA).
PCR arrays Following RNA extraction, total 7-week-old
mouse or human RNA (1 μg) was reverse-transcribed using
the RT2 First strand kit (SA Bioscience), as recommended by
the manufacturer. The Mouse Inflammatory Cytokines and
Receptors PCR Array (SA Bioscience) was performed using
cerebral cortex tissue cDNA (N=3) according to the manu-
facturers protocol. The Human Inflammatory Cytokines and
Receptors PCR Array (SA Bioscience) was performed on
both the human frontal cortex and cerebellum according to
the manufacturer s protocol (N=3; NPC1 patients
UMB#4237, 5372, M4002M, and controls UMB#754, 914,
1841). Genes for which an undetermined Ct value was
reported in at least one sample were excluded from analysis.
All raw data are available in Supplemental Table 1.
Validation of PCR array data Total RNA (10 μg) was
reverse-transcribed into cDNA according to the manufacturers
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instructions using the High-Capacity cDNA archive kit
(Applied Biosystems). The following TaqMan assays
(Applied Biosystems) were used to assess the expression level
of several genes with altered expression including: Ccl8
(Mm01297183), Il1b (Mm01336189), Cxcl9 (Mm00434946),
C3 (Mm00437858) and Cxcl10 (Mm00445235); C3
(Hs01100879), C4A (Hs00167147), CXCL3 (Hs00171061),
CXCL5 (Hs01099660), IL10RA (Hs00155485), CEBP
(Hs00270923), TOLLIP (Hs01553188) SPP1 (Hs00959010),
CCR5 (Hs00152917), and CCL5 (Hs00174575). All gene as-
says were first validated using serial dilutions of control cDNA
and compared to Gapdh/GAPDH (mouse Ccl8, Cxcl9, Il1b,
and Cxcl10 assays; human CXCL3, CXCL5, CEBP, CCR5,
TOLLIP, and SPP1 assays), or Actb/ACTB assays (mouse C3
assay; human C3, C4A, CCL5 and IL10RA assays). We were
unable to confirm the probes for the following genes due to low
expression levels in the tissues we tested: LTB, IL1F9, IL5 and
IL9R.
Quantitative real-time PCR (qPCR) was performed
using an Applied Biosystems 7900 real-time PCR system.
Each sample was analyzed in triplicate, using 50 ng of
total cDNA for each reaction. Human gene expression
was validated on the full set of NPC1 patients and con-
trols available (seven samples for each group for frontal
cortex; four samples for each group for cerebellum).
Mouse gene expression was validated on the 7-week-old
samples used for the PCR array, as well as on an inde-
pendent set of 1, 3, 5, 7, 9, and 11 week-old samples. The
relative quantification of gene expression was performed
with the comparative cycle number measured with the
threshold method (CT) (Livak and Schmittgen 2001),
using the control samples as a reference for quantification,
and was plotted with mean and standard deviation (SD).
Log10 transformed quantitation values were used to
perform statistical analyses on normally distributed
datasets. An unpaired t-test with Welchs correction, when
appropriate, was performed to assess the significance of
the difference of means between control and mutant or
patient samples. A list of all genes or proteins analyzed in
this study is provided in Supplemental Table 1.
Pathology study on human brain post-mortem sample Fixed
tissue slices embedded in paraffin were obtained from the
NICHD Brain and Tissue Bank for three patients and
controls. Tissues were stained using a mouse anti-Human
CD68 antibody (EBM11, Dako) and developed using the
Vectastain ABC kit (Vector) using standard protocols.
Results
Expression of genes associated with inflammation in Npc1
mutant mouse cerebral cortex tissue
7-Week Npc1 mouse analysis We conducted an inflammation-
targeted gene expression analysis from cerebral cortex tissue
isolated from 7-week-old Npc1+/+ and Npc1−/− mice. Twelve
genes (Table 1) met our screening criteria of an absolute fold-
change ≥2 and p-value ≤0.1. These 12 genes include members
of the complement pathway, cytokine/chemokine family and
the interleukin family. Il1b, Ccl8, C3, Cxcl9 and Cxcl10 genes
were further validated via qPCR (Supplemental Fig. 1) with
significantly increased expression of Il1b, Ccl8 and Cxcl10
genes. C3 and Cxcl9 expression appeared to be increased;
however, not significantly (p-values 0.06 and 0.17 respective-
ly), likely due to the high variability in expression levels for
C3 and Cxcl9 in the mutant and control groups respectively.
Npc1 mouse model inflammation time course study We
additionally investigated the mRNA expression of the same
five genes listed above as well as Ccl3 in an independent set
of Npc1mouse cerebral cortex tissue collected at 1, 3, 5, 7, 9
and 11 weeks of age (Fig. 1). The expression of all genes
analyzed with the exception of Ccl8 was significantly in-
creased in the Npc1−/− mouse tissue compared to control
littermates from 3 weeks of age across the time course study.
Only Cxcl10 expression was found to be significantly in-
creased at the 1 week time point.
Effect of Ccl3 up-regulation in Npc1 pathological
process
Ccl3 gene expression has previously been described as
increased in the Npc1 mouse model (Liu et al 2010; Aqul
et al 2011; Lopez et al 2012a). Our time course study
indicated an early alteration of Ccl3 expression (Fig. 1),
Table 1 Genes significantly altered in cerebral cortex tissue from 7-
week Npc1−/− mice relative to control (Npc1+/+) mouse tissue. A total
of 12 transcripts were altered with a fold-change of ≥2 (p≤0.1)
Gene symbol p-
value
Fold-
change
C3 0.04 3.8
Ccl11 0.09 2.7
Ccl3 0.01 6.3
Ccl4 0.06 3.5
Ccl5 0.03 2.1
Ccl8 0.03 7.6
Cxcl1 0.02 4.1
Cxcl10 0.01 7.7
Cxcl11 0.03 2.9
Il1a 0.07 2.2
Il1b 0.04 3.6
Il1r2 0.06 2.0
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progressive dysregulation in the Npc1 mouse model and
increased levels of CCL3 protein in cerebrospinal fluid from
NPC1 patients (see below). These data, combined with the
prior observation (Wu and Proia 2004) that deletion of the
Ccl3 gene delayed the onset of neurological symptoms and
increased survival in a mouse model of GM2-gangliosidosis
(Sandhoff disease, HexB mutations), prompted us to further
characterize the role of Ccl3 in NPC1 pathology. We hy-
pothesized that, similarly to observations in the HexB mu-
tant mouse, deletion of Ccl3 would improve the phenotype
in Npc1 mutant mice. To test this hypothesis, we
intercrossed Ccl3-deficient mice with Npc1+/− mice to pro-
duce Npc1+/−Ccl3+/−mice. These mice were then intercrossed
to obtain Npc1+/+Ccl3+/+, Npc1−/−Ccl3+/+, Npc1−/−Ccl3+/− and
Npc1−/−Ccl3−/− animals on a mixed C57BL/6 and BALB/c
background. Most of the Npc1−/−Ccl3+/− and Npc1−/−Ccl3−/−
animals showed weight loss and age of death similar to
Npc1−/−Ccl3+/+ animals, with the notable exception of two
double mutant mice that survived to ∼13 weeks of age.
Npc1 deficiency in a C57BL/6 genetic background is more
severe than in the BALB/c background (Parra et al 2011), thus
the mixed genetic background could mask a beneficial effect
associated with Ccl3 deletion. We therefore backcrossed
Npc1+/−Ccl3+/− mice to the original BALB/c Npc1+/− animals
for five generations (∼97 % BALB/c) and compared weight
loss and survival of these animals. No significant difference
between Npc1−/−Ccl3−/− and Npc1−/−Ccl3+/+ mice was
observed (Supplemental Fig. 2). Female Npc1−/−Ccl3+/− and
Npc1−/−Ccl3−/−mice gained and maintained a closer-to-normal
weight than Npc1−/−Ccl3+/+ mice between P40 and P55 days
approximately, but all animals with a deletion of the Npc1 gene
had lost 20 % of their maximal weight by approximately
75 days of age. Males with the Npc1 deletion showed compa-
rable weights at all ages independent of the Ccl3 genotype.
Expression of genes associated with inflammation in
human NPC1 frontal cortex and cerebellar tissue
We tested the presence of neuroinflammation in NPC1 hu-
man brains by CD68 immunostaining which is a common
microglial activation marker. Frontal cortex and cerebellar
tissue from control (Fig. 2a, b) and NPC1 patients (Fig. 2c,
d) were analyzed where increased CD68 staining was ob-
served for the NPC1 tissues.
A qPCR array analysis, analogous to that described above
for the Npc1 mouse model, was performed on human frontal
cortex and cerebellar brain tissue from control and NPC1
subjects. Nine genes (Table 2a) and ten genes (Table 2b) were
differentially expressed with an absolute fold-change ≥2 and
p-value≤0.1 for frontal cortex and cerebellar tissue, respec-
tively. Unexpectedly, only one identified gene, complement 3
(C3), was concordantly altered in mouse brain, human frontal
cortex, and human cerebellar tissue. Interestingly, CCL5 was
Fig. 1 Validation of mouse inflammation PCR array results. qPCR
validation of six genes in Npc1+/+ (white columns) and Npc1−/− (black
columns) cerebral cortex. One-week-old control mice were used as
reference group for the relative quantitation, except for Ccl3 for which
the 3-week-old control group was used as 1-week-old mice had
undetectable transcript levels (BLD: below limit of detection). Mean
and standard deviation are shown for each group (N=4). An unpaired
t-test with Welchs correction, when necessary, was performed to
determine the significance of the difference in means between the
log10 values of control and mutant mice relative quantitation at each
age: *p-value≤0.05; **p-value≤0.005; ***p-value≤0.0001
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increased in Npc1 mutant mouse cerebral cortex and in cere-
bellar tissue from post-mortem NPC1 patients.
qPCR validation was performed for eight of these
genes in both frontal cortex and cerebellar tissue from
controls and NPC1 patients. We found six genes (C3,
CEBP, CCR5, CXCL5, IL10RA, and SPP1) in which
significant changes were observed in at least one of
the tissue types tested (Supplemental Fig. 3). C3 expres-
sion was higher in NPC1 patients than the age-matched
controls, except for the 5-year-old patient (Supplemental
Fig. 3a). We additionally evaluated C4A (Supplemental
Fig. 3b) and CXCL3 (Supplemental Fig. 3f) gene ex-
pression by qPCR, which displayed strong fold-change
but not significant p-values on the PCR array data. In
general, the expression levels of the ten genes tested
were variable within the patient group, which may be
related to the degree of variability in disease severity.
The 5-year-old male patient showed normal levels of
expression of all tested genes in both brain tissue types.
The available clinical information indicates that he died
before manifesting neurological symptoms, which might
explain why none of these inflammatory-related genes
showed altered expression.
Characterization of neuroinflammatory markers
in cerebrospinal fluid from NPC1 patients
To expand and translate our findings from the mouse and
human arrays, we evaluated neuroinflammatory markers in
the cerebrospinal fluid from a cohort of NPC1 patients
enrolled in the NIH Natural History/Observational study.
This was accomplished by measuring the concentrations of
31 interleukins, cytokines and chemokines in the cerebro-
spinal fluid of NPC1 patients (n=42) and pediatric controls
(n=30), using multi-analyte ELISA-based profiling (MAP).
CSF levels of IL-3 (p=0.0005), IL-16 (p=0.04), CXCL5 (p
=0.03) and CCL3 (p<0.0001) were increased in NPC1 sub-
jects compared to controls, and CSF levels of IL-4 (p<
0.0001), IL-10 (p=0.02), IL-13 (p=0.006) and IL-12p40
(p<0.0001) were decreased (Figs. 3 and 4a). Trends were
observed for IL-1α (p=0.06) and IL-7 (p=0.07), while no
statistical differences were detected for the interleukins IL-5,
IL-6, IL-15 and IL-18 (Supplemental Fig. 4) and MCP-1,
MMP3, ICAM-1, or stem cell factor (Supplemental
Fig. 5).
The classical pro-inflammatory cytokine TNFα has been
shown to be elevated in astrocytes from 7-week-old Npc1−/−
mice (Wu et al 2005). Therefore we hypothesized that TNFα
would be elevated in the CSF in NPC1 patients as a reflection
of the neuroinflammation. Most NPC1 patients had
undetectable levels of TNFα in CSF as measured using MAP
(limit of detection 1.4 pg/mL). Using a high-sensitivity ELISA
kit specific for TNFα, we still found that the majority of tested
samples were below the limit of detection (0.1 pg/mL). The
TNFα transcript was also measured via the array analysis
where no changes were detected in the mouse or human cere-
bellum but elevation was observed in the human frontal cortex
(Table 2a).
Based on the elevated levels of C3 in both mouse and
human tissue samples, we were interested in determining if
CSF levels of C3 were altered. As C3 was not evaluated in
the MAP experiment, we measured C3 concentrations in
CSF from a subset of NPC1 patients and controls from our
cohort. No significant differences were observed. Mean CSF
C3 levels were 1096±333 ng/mL and 726.6±58.83 ng/mL
for control (n=11) and NPC1 (n=14) samples respectively
(p=0.8). Another similarity between the array data and CSF
data was for CXCL5. This gene was found to be elevated in
NPC1 patients tissues (3.9-fold, p=0.003 in cerebellum;
4.0-fold, p=0.03 in cortex) compared to controls. Furthermore,
in the CSF the mean CXCL5 level was found to be mildly
elevated in the NPC1 patient cohort (Fig. 3g).
Fig. 2 Representative human tissue stained with the macrophage/
microglia marker CD68. The top row shows cortex (400x) from control
(a) and NPC1 (c); The bottom shows cerebellum (200X) from control
(b) and NPC1 (d). Staining was performed on sections from the three
patients (UMB#4770, 5372, and M4003M) and respective controls for
which brain sections were available. Images are from patient
UMB#5372, and control UMB#914
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Approximately half of the patients in the NIH Natural
History cohort are taking miglustat off-label; therefore, we
investigated whether miglustat therapy had any effect on the
concentrations of the eight significantly modified markers. IL-
3 and IL-13 concentrations were decreased slightly when
comparing miglustat treated and untreated patients (p-value
<0.05; Supplemental Fig. 6a, e). Since individual responses
could be masked by the large degree of inter-patient variation,
we compared CSF concentrations of these same eight inflam-
mation markers in five NPC1 patients for whom we had serial
cerebrospinal fluid samples prior to and after initiation of off-
label miglustat use. In this subset of five patients only IL-10
had a coordinate response (Supplemental Fig. 6d). More ex-
tensive, long-term analysis is needed to establish if IL-10 CSF
levels provide a useful indication of neuroinflamation in
NPC1 based on these results.
Given the phenotypic heterogeneity observed in NPC1, we
were interested in determining if cerebrospinal fluid concen-
trations of the markers correlated with NPC1 disease status.
Using the NIH NPC1 neurological severity score (Yanjanin et
al 2010), we observed a significant correlation between CCL3
levels and annual severity increment score (neurological se-
verity score/age; r2=0.17, p-value<0.002; Fig. 4b).
Discussion
This discovery based analysis revealed several inflammato-
ry markers which are altered in the tissue of Npc1 mutant
mice or NPC1 human tissue specimens relative to controls.
The majority of candidate markers from the PCR array in
NPC1 post-mortem tissue displayed increased expression in
the NPC1 samples relative to controls with only one tran-
script displaying decreased expression. Inflammation in hu-
man NPC1 post-mortem tissue was also confirmed via
CD68 staining for activated microglia in both the cerebel-
lum and frontal cortex. Furthermore, measurements of in-
flammatory markers in cerebrospinal fluid from NPC1
patients and pediatric controls show marked differences for
a small set of inflammatory proteins.
Complement C3 was the only gene to be found altered in
all samples (mouse cerebral cortex, human cerebellum and
human frontal cortex). The expression of some components
of the complement pathway had previously been reported as
increased in Npc1 mouse model cerebellum, specifically
C1q, C2, C3, C4b and the two receptors C3ar1 and C5r1
(Liao et al 2010; Vazquez et al 2011; Lopez et al 2012a, b).
All cell types in the brain are able to produce complement
factors (Veerhuis et al 2011), and the complement pathway
contributes to the inflammatory process of several brain
diseases, including Alzheimer disease (Rubio-Perez and
Morillas-Ruiz 2012). A recent study investigating the role
of the complement pathway in neuron survival in NPC1
revealed that complement gene deletion did not rescue neu-
ronal death, and therefore innate inflammation, while pres-
ent in NPC1, is not the major causative factor of
neurodegeneration (Lopez et al 2012b).
Activated microglia was observed in brain tissue of the
Npc1 mouse model in several studies via positive CD68
staining (Liu et al 2009; Smith et al 2009; Liao et al 2010;
Ramirez et al 2010; Aqul et al 2011; Pressey et al 2012). We
also observed this marker of activated microglia in post-
mortem tissue from NPC1 patients while it was absent in
control tissue. The common classification of activated mi-
croglia stems from the classical morphological change and
the production of neurotoxin or neurotrophic molecules as
well as microglia migration to the site of injury.
Table 2 a Array data displaying altered transcripts in NPC1 human
post-mortem frontal cortex tissue versus control tissue. Nine transcripts
were altered with a fold-change of ≥2 (p≤0.1). b Transcripts found to
be altered in NPC1 post-mortem cerebellar tissue versus control tissue.
A total of ten transcripts were altered with a fold-change of ≥2 (p≤0.1).
The two genes listed in the sub-table for each tissue type were found to
display drastic fold changes however with p-values>0.1, but were
chosen to validate via qPCR
Gene symbol p-value Fold-change
(A) Human frontal cortex
C3 p<0.005 4.5
CCL13 0.02 3.4
CXCL5 0.03 4.0
IL10RA 0.03 3.8
IL13RA1 0.02 2.5
IL17C 0.01 3.9
IL1R1 0.06 2.7
LTB 0.07 2.0
TNF 0.09 5.6
C4A 0.22 17.3
CXCL3 0.25 5.1
(B) Human cerebellum
C3 p<0.005 3.3
CCL5 0.03 5.5
CCR5 0.08 5.5
CEBPB 0.01 2.7
CXCL5 p<0.005 3.9
IL10RA 0.10 7.9
IL5 0.05 -2.7
IL9R 0.05 2.3
SPP1 0.05 3.5
TOLLIP 0.05 2.1
C4A 0.35 3.7
CXCL3 0.15 3.0
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Several classical inflammatory markers have been
reported as being dysregulated in the Npc1 mouse model,
including IL1β (Baudry et al 2003; Repa et al 2007) and
TNFα (Li et al 2005; Wu et al 2005; Langmade et al 2006;
Aqul et al 2011). In our expression study of mouse brain
tissue, we identified Il1b as being increased. However, it
was not modified in human tissues. Similarly, TNFα was
only detected as upregulated in NPC1 human cortex tissue.
Additionally, both markers were undetectable in cerebrospi-
nal fluid of most NPC1 patients and controls. Other classical
markers of inflammation, such as IL-6, IL-8, and MCP1,
had comparable levels in patients and controls cerebrospinal
fluid, which suggests that the neuroinflammatory mecha-
nism present in NPC1 might be different from a classical
neuroinflammation process reported in other disorders.
Eight of the 31 inflammatory markers tested showed
significantly different CSF concentrations in NPC1 patients
compared to pediatric controls including decreased levels of
IL-4 and 10. It has been shown that activated microglia
result in the production of IL-4 and IL-10 to reduce neuron
degeneration (Park et al 2005; Henry et al 2009); however,
the mechanism for IL-10 production within the CNS is still a
topic of ongoing research (Chabot et al 1999). Interestingly,
little to no change was noted in any of the analyte levels
measured from NPC1 patients on miglustat versus those not
on miglustat treatments, and only IL-10 displayed a slight
decrease after initiation of miglustat therapy. The fact that
miglustat treatment did not change the CSF marker levels in
NPC1 patients would suggest that the potential anti-
inflammatory properties of miglustat may affect classical
markers, but not those found to be significantly altered in
this study.
From our gene expression experimental results Ccl3 was
found to be altered in the cerebral cortex of 7-week-old
Npc1 mutant mice. In an effort to understand if deletion of
this gene would improve the survival and therefore the
phenotype of NPC1 disease, we generated a double mutant
mouse model. In contrast to the Sandhoff disease model, the
genetic deletion of Ccl3 in the Npc1 mouse model did not
show any improvement with regards to survival or weight
loss in the Npc1 mutant animals. This suggests that the
origins of the brain inflammation observed in the two lyso-
somal storage diseases are likely different. In particular,
macrophage infiltration from the periphery is observed in
Sandhoff disease (Wu and Proia 2004), and does not appear
to occur in NPC1 disease (Lopez et al 2012a). The effect of
Ccl3 deletion in Npc1 mice has been reported in the F1
generation (Lopez et al 2012a). In agreement with our
finding, the authors did not observe an improvement in the
double Npc1 and Ccl3 mutant phenotype compared to the
Npc1 mutants. However, they reported a lower weight in
double-mutant males compared to Npc1−/− Ccl3+/+, and a
slightly shorter survival rate, but no differences between
females. On the contrary, we observed a small temporary
benefit in weight gain for Npc1−/− females with deletion of
one or two Ccl3 alleles, and no differences for males.
Genetic background might have an impact on this specific
trait, as Npc1−/− mice have a more severe phenotype on a
C57BL/6 background than on a BALB/c background (Parra
et al 2011). Considering that we backcrossed our mice for
five generations, the effect of the C57BL/6 background was
probably negligible in our cohort of animals.
Despite the absence of a positive effect of Ccl3 deletion
on NPC1 disease process, we identified increased concen-
trations of CCL3 in cerebrospinal fluid of NPC1 patients
compared to age-matched controls. Correlation of CCL3
levels with disease severity and the clear separation of the
patient group compared to controls make CCL3 an
Fig. 3 Cerebrospinal fluid inflammation markers. Log10 transformed
concentrations of seven cytokines in cerebrospinal fluid from controls
(circles) and NPC1 patients (squares). Mean and standard deviation are
shown for each group. An unpaired t-test with Welchs correction when
necessary was performed to determine significance
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interesting biomarker for evaluation of NPC1 disease status.
Future studies aimed at developing an appropriate pharma-
cological therapy for NPC1 disease will be strengthened by
the ability to monitor CCL3 CSF concentration in these
patients.
To summarize, extensive work conducted within the last
decade has documented a progressive inflammatory process
occurring in NPC1 disease. The vast majority of this work
has focused on the Npc1 mouse model. We therefore inves-
tigated the neuroinflammatory process in NPC1 patients.
Based on our studies, we have identified several potential
inflammatory markers that may prove useful in correlating
with neurological progression or be utilized to facilitate the
design and implementation of clinical trials to demonstrate
potential efficacy of candidate therapies.
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